The stock of Takeda Pharmaceutical Company Limited (NYSE:TAK) decreased by -$0.06 on Tuesday to finish at $15.21, down -0.39 percent. The last five days have seen an average of 2,015,320 shares of common stock traded. 11 times new highs were reached in the current year, with a fall of -$0.39. The average number of shares traded over the last 20 days was 3,041,475, while the average volume over the last 50 days totaled 2,283,056.
TAK stock dropped -0.39% since last month. On 08/01/23, the company’s shares reached a one-month low of $14.92. The stock touched a high of $17.15 on 04/06/23, after rallying from a low of $12.28 in 52 weeks. The price of TAK stock has declined by -2.50% or -$0.39 this year, reaching a new high 11 times. Still, the stock price is down -11.31% from the 52-week high.
Valuation Metrics
Takeda Pharmaceutical Company Limited (TAK) has a trailing price-to-earnings (P/E) ratio of 22.91. Beta for the stock is 0.64. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 1.70, the price-to-book (PB) ratio of 0.99.
Financial Health
For the recent quarter, Takeda Pharmaceutical Company Limited’s quick ratio was 0.60, while its current ratio was 1.00, indicating its inability to pay off its debt. The company’s long-term debt to equity ratio for the recent quarter is 0.63, and the total debt to equity ratio is 0.69. As far as profitability goes, gross margin for the trailing twelve months is 69.10% percent. Takeda Pharmaceutical Company Limited’s EBITDA margin for the recent year was 32.84%, whereas its operating margin stood at 12.40% for the same period. Based on annual data, it had gross profit of $20.6 billion and revenue of $29.8 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. TAK’s return on assets (ROA) during the last 12 months has been 2.10%. There was a 4.00% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 4.60%.
Earnings Surprise
A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $27.9 billion, while revenues rose by 100.0% to $0.0. EBITDA was $2.48 billion for the quarter. At the end of Takeda Pharmaceutical Company Limited’s most recent quarter, its liabilities totaled 57.46 billion, while its total debt was $5.24 trillion.
Technical Picture
Here’s a quick look at Takeda Pharmaceutical Company Limited’s (TAK) price momentum from a technical perspective. As of 15 August, the RSI 9-day stood at 40.99%, suggesting the stock is Neutral, with a 8.22% historical volatility rate.
The stochastic %K and %D were 39.70% and 43.45% respectively, while the average true range (ATR) was 0.16. Based on the 14-day stochastic reading of 32.58%, the RSI (14) reading is 41.65%. On the 9-day MACD Oscillator, the stock is at -0.02, and the 14-day reading is at -0.02.
Analyst Ratings
In its most recent analyst report, BofA Securities raised its rating on Takeda Pharmaceutical Company Limited (NYSE: TAK) to a Buy. Prior to this, analysts firm rated the stock as a Neutral. Analysts have assigned Takeda Pharmaceutical Company Limited (TAK) an Overweight rating. TAK is a stock that is recommended for selling by 0 brokerage firms, while 12 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 6 others recommend it as a buy.
What is TAK’s price target for the next 12 months?
The current consensus forecast for the stock is between $12.80 and $20.67, with a median target price of $16.75. In analyzing these forecasts, the average price target given by analysts for Takeda Pharmaceutical Company Limited (TAK) is $16.63.
